Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study.
about
Pharmacological treatments for prostate cancer.Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges.New standards in the chemotherapy of metastatic hormone-refractory prostate cancer.Second-line therapy for castrate-resistant prostate cancer: a literature review.Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles.Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer--a phase II trial.
P2860
Vinorelbine and estramustine in androgen-independent metastatic prostate cancer: a phase II study.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Vinorelbine and estramustine i ...... tate cancer: a phase II study.
@en
Vinorelbine and estramustine i ...... tate cancer: a phase II study.
@nl
type
label
Vinorelbine and estramustine i ...... tate cancer: a phase II study.
@en
Vinorelbine and estramustine i ...... tate cancer: a phase II study.
@nl
prefLabel
Vinorelbine and estramustine i ...... tate cancer: a phase II study.
@en
Vinorelbine and estramustine i ...... tate cancer: a phase II study.
@nl
P2093
P2860
P1433
P1476
Vinorelbine and estramustine i ...... tate cancer: a phase II study.
@en
P2093
P2860
P304
P356
10.1002/1097-0142(20001015)89:8<1824::AID-CNCR24>3.0.CO;2-R
P407
P577
2000-10-01T00:00:00Z